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Abstract
Objective: To compare the cost-effectiveness of generic psychological therapy (counseling) with rou-
tinely prescribed antidepressant drugs in a naturalistic general practice setting for a follow-up period of
12 months.
Methods: Economic analysis alongside a randomized clinical trial with patient preference arm. Compari-
son of depression-related health service costs at 12 months. Cost-effectiveness analysis of bootstrapped
trial data using net monetary benefits and acceptability curves.
Results: No significant difference between the mean observed costs of patients randomized to antide-
pressants or to counseling (£342 vs £302, p= .56 [t test]). If decision makers are not willing to pay
more for additional benefits (value placed on extra patient with good outcome, denoted by K , is zero),
then we find little difference between the treatment modalities in terms of cost-effectiveness. If decision
makers do place value on additional benefit (K > £0), then the antidepressant group becomes more
likely to be cost-effective. This likelihood is in excess of 90% where decision makers are prepared to
pay an additional £2,000 or more per additional patient with a good global outcome. The mean values
for incremental net monetary benefits (INMB) from antidepressants are substantial for higher values of
K (INMB = £406 when K = £2,500).
Conclusion: For a small proportion of patients, the counseling intervention (as specified in this trial) is
a dominant cost-effective strategy. For a larger proportion of patients, the antidepressant intervention
(as specified in this trial) is the dominant cost-effective strategy. For the remaining group of patients,
cost-effectiveness depends on the value of K . Since we cannot observe K , acceptability curves are a
useful way to inform decision makers.
Keywords: Cost-effectiveness analysis, Depression, Antidepressants, Counseling
Depressive disorders are common, cause significant disability for the individual, and place a
substantial burden on health and social services. Most depressive disorders are dealt with in
a primary care setting. Psychological therapies are being proposed as a potential alternative
to the major treatment modality, antidepressant drugs. Surveys suggest patients may prefer
nondrug psychological therapies such as counseling (11). At present little evidence exists to
inform decision makers about the relative effectiveness and cost-effectiveness of counseling
therapy compared with antidepressant therapy for treatment of depression. In particular,
generic counseling is a widely available but poorly evaluated form of psychological therapy
in primary care.
Two recent studies have found no significant differences between treatment groups for
a range of outcome measures including cost. Harvey et al. (7) carried out a randomized
controlled trial (RCT) and economic evaluation comparing counseling in primary care with
usual GP care. Bower et al. (3) carried out an RCT and cost-effectiveness analysis comparing
nondirective counseling, cognitive-behavior therapy, and usual general practitioner care.
As in most cases, these studies were designed to detect clinical differences and economic
analysis was “piggybacked” on. Decision makers must not conclude that these treatments are
equally cost-effective/cost-ineffective; the absence of evidence is not evidence of absence.
Since economic data often have highly skewed distributions, a larger sample size may
be required. However, this may generate ethical (clinically overpowered) and financial
problems for randomized trials. The Counselling and Antidepressants in Primary Care
(CAPC) study was set up to determine the relative effectiveness and cost-effectiveness of
generic counseling and antidepressant drugs for the treatment of mild to moderate major
depressive episodes in a general practice setting. This paper describes the economic analysis
only. The economic evaluation aims to establish the change in resource use and the change
in effectiveness brought about by a study intervention (generic counseling) compared with
a standard intervention (antidepressant drugs). The economic evaluation ran alongside the
prospective RCT and generated patient-specific cost and effect data. To overcome some of
the problems of piggyback economic trials, the bootstrapping technique is used to simulate
repeated trials.
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METHODS
Details of the trial methodology and clinical outcomes have been published elsewhere
(6). Patients were randomized to either counseling or antidepressants. Patients refusing
randomization but agreeing to participate in the patient preference trial were given the
treatment of their choice. Treatments and follow-up were identical in the randomized and
patient preference groups.
The study was designed to compare treatments as they are provided in day-to-day
practice. Thus, clinical responsibility rested with the general practitioner (GP), and the
doctor’s usual follow-up procedure was encouraged. Patients receiving antidepressants were
prescribed the drug most suited to their symptoms. A prescribing protocol was suggested by
the study team: dothiepin (150 mg) taken at night; fluoxetine (20 mg) taken once daily; and
lofepramine (140–210 mg) taken daily in divided doses. GPs were free to issue a drug not
on the schedule if they judged it necessary. Substitution of drugs was permitted during the
trial, but the GP was asked to continue treatment at full British National Formulary (BNF)
recommended dosage for at least 4 months after remission.
Patients receiving counseling were offered six 50-minute sessions funded by the trial
to take place weekly. Six sessions were considered appropriate, since this is comparable to
the amount of contact time routinely provided in primary care and workplace counseling
services. Extra sessions were requested by some patients and suggested by counselors or
GPs, but these were restricted to a maximum of two.
Economic analysis consisted of two stages: a) a detailed costing study quantified re-
source use in the two treatment arms for a follow-up period of 12 months; and b) cost data
and outcomes data collected in the clinical trial were synthesized in a cost-effectiveness
analysis.
The costing study involved the identification, measurement, and valuation of resource
use. For the 12-month period after enrollment, all depression-related health service resources
used were recorded. All GP consultations, drugs prescribed, and use of GP-arranged coun-
seling were recorded from patient notes. Hospital psychiatric outpatient and inpatient visits
were abstracted from case notes. The costs used in Tables 1 and 2 are for the 12-month
study period and are categorized as: a) all antidepressants prescribed; b) all counseling
received; c) all direct depression treatment combined (antidepressants and counseling to-
gether, a + b); d) all GP consultations relating to depression (as indicated by notes); e) all
GP consultations (including d); f) psychiatric inpatient hospital stays; and g) psychiatric
outpatient hospital visits. The relevant aggregated total is given as: all depression-related
health services (c + d + f + g).
Unit cost data were obtained from Netten et al. (9), BNF (5), and invoices from coun-
selors in the trial. Analysis of cost data follows Barber and Thompson (1) and includes
measures of location (mean and median), variability (interquartile range), shape of dis-
tribution (skew: coefficient of asymmetry of distribution), and precision (95% confidence
intervals). Inferences about the average cost differences are based on comparison of arith-
metic means given by the t test. Results are also presented for the nonparametric Mann
Whitney U test, addressing differences in medians and shape of the cost distribution be-
tween the groups. Costs were not trimmed for outliers or transformed, so analysis is based
on mean costs.
Barber and Thompson (2) also advocate the use of the bootstrapping technique to
confirm the validity of results based on a comparison of mean costs using the standard t
test. This is especially important where sample size is low and severe skew is present. There
is ongoing methodologic debate over the robustness of the bootstrap and methods based on
normality theory compared with a Bayesian approach (10). In this study we chose to follow
the Barber and Thompson approach.
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Table 1. Twelve-month Resource Use (Randomized Patients)
Antidepressant Counseling Mann-
group group Whitney
Cost (n = 51) (n = 52) t test U test
All Mean (SE) £84.16 (12.45) £21.69 (5.97) p < .001 p < .001
antidepressants 95% CI L: £59.14 L: £9.71
U: £109.19 U: £33.68
Median £46.38 £0
IQR £128.78 £30.86
Skewness 1.33 2.22
All Mean (SE) £7.06 (2.79) £94.23 (7.0) p < .001 p < .001
counseling 95% CI L: £1.49 L: £80.18
U: £12.91 U: £108.28
Median £0 £120
IQR £0 £80.00
Skewness 2.88 −0.48
All direct Mean (SE) £89.57 (12.04) £115.92 (10.0) p = .095 p = .031
depression 95% CI L: £65.39 L: £95.83
treatment U: £113.75 U: £136.01
Median £73.39 £120
IQR £126 £78.92
Skewness 1.25 0.48
Depression- Mean (SE) £70.20 (6.93) £56.54 (9.76) p = .255 p = .025
related GP 95% CI L: £55.98 L: £36.94
visits U: £84.42 U: £76.14
Median £60 £30
IQR £75 £90
Skewness 1.08 2.43
All GP visits Mean (SE) £132.65 (10.51) £126.63 (12.44) p = .713 p = .446
95% CI L: £111.53 L: £101.65
U: £153.76 U: £151.61
Median £135 £105
IQR £90 £86.25
Skewness 1.50 1.26
Psychiatric Mean (SE) £95.13 (48.08) £36.18 (22.90) p = .268 p = .513
inpatient 95% CI L: −£1.45 L: −£9.81
U: £191.70 U: £82.16
Median £0 £0
IQR £0 £0
Skewness 4.78 6.03
Psychiatric Mean (SE) £86.10 (19.07) £89.72 (19.05) p = .893 p = .664
outpatient 95% CI L: £47.79 L: £51.48
U: £124.40 U: £127.96
Median £0 £0
IQR £182.96 £182.96
Skewness 1.69 2.49
All depression- Mean (SE) £343.64 (61.87)b £301.63 (37.72)c p = .561 p = .777
related health 95% CI L: £219.45 L: £225.91
servicesa U: £467.82 U: £377.35
Median £265.30 £235.74
IQR £262.01 £244.10
Skewness 3.54 2.24
aAntidepressants + counseling + GP depression-related visits + psychiatric inpatient admissions + psychiatric
outpatient visits.
bMean of 25 prescriptions for antidepressants, 5 depression-related GP visits. In total 7 people in this group
received counseling; there were 9 inpatient admissions and 20 outpatient visits.
cMean of 2 prescriptions for antidepressants, 4 depression-related GP visits. In total 47 people in this group
received counseling; there were 7 inpatient admissions and 24 outpatient visits.
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Table 2. Twelve-month Resource Use (Patient Preference)
Antidepressant Counseling Mann-
group group Whitney
Cost (n = 76) (n = 139) t test U test
All Mean (SE) £76.08 (10.38) £35.76 (6.23) p < .001 p < .001
antidepressants 95% CI L: £55.41 L: £23.42
U: £96.75 U: £48.10
Median £32.73 0
IQR £104.99 £48.45
Skewness 1.50 2.78
All Mean (SE) £3 £106.03 (4.54) p < .001 p < .001
counseling 95% CI L: −£2.49 L: £97.06
U: £8.49 U: £115
Median 0 £120
IQR 0 £40
Skewness 8.84 −0.26
All direct Mean (SE) £75.28 (10.91) £141.53 (7.69) p < .001 p < .001
depression 95% CI L: £53.55 L: £126.32
treatment U: £97.01 U: £156.75
Median £30.15 £120
IQR £88.74 £76.70
Skewness 1.83 1.47
Depression- Mean (SE) £66.12 (6.25) £47.24 (5.27) p = .027 p = .001
related GP 95% CI L: £53.68 L: £36.82
visits U: £78.56 U: £57.66
Median £60 £15
IQR £71.25 £75
Skewness 1.17 1.91
All GP visits Mean (SE) £129.47 (8.57) £115.79 (8.97) p = .319 p = .039
95% CI L: £112.41 L: £98.05
U: £146.54 U: £133.53
Median £120 £105
IQR £105 £120
Skewness 0.86 2.42
Psychiatric Mean (SE) £39.15 (13.31) £39.62 (12.82) p = .982 p = .735
inpatient 95% CI L: £12.65 L: £14.26
U: £65.66 U: £64.97
Median 0 0
IQR 0 0
Skewness 3.86 5.32
Psychiatric Mean (SE) £89.07 (19.16) £107.39 (14.75) p = .454 p = .427
outpatient 95% CI L: £50.91 L: £78.21
U: £127.23 U: £136.57
Median 0 0
IQR £91.48 £182.96
Skewness 2.88 1.97
All depression- Mean (SE) £263.41 (33.84)b £335.63 (24.86)c p = .084 p = .005
related health 95% CI L: £196.04 L: £286.48
servicesa U: £330.77 U: £384.77
Median £184.33 £224.52
IQR £249.69 £272.78
Skewness 2.3 1.69
aAntidepressants + counseling + GP depression-related visits + psychiatric inpatient admissions + psychiatric
outpatient visits.
bMean of 55 prescriptions for antidepressants, 8 depression-related GP visits. In total 2 people in this group
received counseling; there were 15 inpatient admissions and 29 outpatient visits.
cMean of 9 prescriptions for antidepressants, 9 depression-related GP visits. In total 126 people in this group
received counseling; there were 25 inpatient admissions and 59 outpatient visits.
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In the clinical trial, the main outcome measures at 12 months were (6):
 Beck Depression Inventory score completed by the patient;
 Time to remission;
 Global outcome, classified as good, moderate, poor, or unknown; and
 The Research Diagnostic Criteria (RDC) completed by the general practitioner.
Remission was defined as an RDC score of less than 4, a Beck score of less than 10, or
clear documentation in the GP notes that the patient was well. “Relapsed” was defined as
deterioration within 6 months of remission, and “recurrence” as deterioration after 6 months
of remission.
Global outcome was assessed by a psychiatrist (NB) blind to treatment allocation, using
the RDC, Beck score, and GP notes. The advantage of this global outcome measure was
that in the absence of RDC or Beck scores, an estimate could be made based on information
obtained from the notes. The outcome was good if the patient responded to treatment within
8 weeks and then remained well, moderate if either the patient was slow to respond but
then remained well or was well initially and then became unwell, and poor if the patient
remained depressed throughout. The criteria for being well were the same as the criteria for
remission.
The cost-effectiveness analysis used the psychiatrist’s assessment of global outcome
as the measure of effectiveness since it represents the most comprehensive measure. This
is presented as a simple binary outcome: probability of good global outcome versus not a
good global outcome.
To account for possible sampling error and to recognize uncertainty around cost and
effect data, a distribution of these estimates was generated using the bootstrapping technique
(4). Bootstrapping is a technique that can simulate a distribution of data by repeatedly
resampling (with replacement) from the observed sample. Since there is covariation between
cost and effect variables, we used 2,000 iterations of resampled estimates for pairs of costs
and effect in all bootstrap simulations. These bootstrapped estimates can then be plotted on
the cost-effectiveness plane (Figure 1).
Figure 1. Antidepressants versus counseling (origin) (randomized patients).
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The origin on the cost-effectiveness plane represents the comparator strategy (coun-
seling), while each data point represents the observed change in cost and effect using the
intervention strategy (antidepressants). This highlights the distribution of cost and effect
data. Points in the southeast quadrant (lower costs, higher benefits) dominate the comparator,
while points in the northwest quadrant (higher costs, lower benefits) are dominated by the
comparator. Points in the remaining two quadrants (northeast and southwest) may or may
not be desirable, depending on decision makers1 values and objectives. Incremental cost
effectiveness ratios (ICER = [cost of antidepressant therapy − cost of counseling)/(effect
of antidepressant therapy − effect of counseling]) are only calculated for points in these
two quadrants. Decision makers must determine their maximum acceptable ICER (denoted
by K ); i.e., how much they would pay for additional units of benefit. Using a range of
values for K , it is possible to simplify from ratios and present results on the incremental
net monetary benefit (INMB) scale. We know that a decision should be made to implement
an intervention when:
ICER = Cost
Effect < K
(since this is when it will be labeled as cost-effective). By rearranging this equation, the
decision rule on the INMB scale is to implement when:
INMB = K .Effect − Cost > 0.
That is, where the monetized value of the change in effect less the change in cost brought
about by the intervention is positive (K can take values 0 − ∞). Since it is not a ratio
statistic, the INMB scale is much easier to analyze.
RESULTS
A total of 103 patients with major depression were randomly allocated to either generic
counseling or antidepressant drugs in primary care. Another 220 patients refused randomiza-
tion but chose their treatment; 64% of them chose counseling. Complete data at 12 months
on global outcome was available for 81 randomized patients and 163 patient preference
patients. For the remaining patients, global outcome was classified as unknown due to in-
sufficient data available to reach a conclusion, caused mostly by patient nonattendance at
12 month GP follow-up. Nine patients randomized to antidepressants had unknown out-
comes, and their mean costs were significantly lower than those with outcome data (£177
vs £379, p = .035). Thirteen patients randomized to counseling had unknown outcomes,
and their mean costs were significantly lower than those with outcome data (£103 vs £368,
p < .001). Twenty-one patients choosing antidepressants had unknown outcomes, and their
mean costs were not different to those with outcome data (£197 vs £287, p = .189). Thirty-
seven patients choosing counseling had unknown outcomes, and their mean costs were not
different to those with outcome data. (£339 vs £334, p = .943). Cost data were complete
for randomized patients, but five patients in the preference arm had missing cost data. In
the primary analysis, patients with missing data are excluded; sensitivity analysis includes
assumed values for randomized patients without outcome data.
Cost Analysis
Randomized Group. There was no significant difference between the two randomized
treatment groups in the cost of all depression-related health care observed in this study for a
period of 12 months after entry to the trial (Table 1). The treatment group to which patients
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were initially randomized (for a period of 8 weeks) led to significantly higher costs for that
form of treatment after 12 months. Thus, patients randomized to counseling have higher
counseling costs at 12 months than those randomized to antidepressants and vice versa.
Since many patients received both treatment modalities within the 12-month period, it is
useful to consider the overall cost of direct depression treatment (counseling +
antidepressants). We observed a significant cost difference between the treatment groups
using the nonparametric test, with higher combined costs for those initially randomized to
counseling. On the other hand, we also observed significantly higher (nonparametric test)
GP depression-related consultation costs in the antidepressant group.
There was no significant difference between the treatment groups in terms of psychiatric
inpatient or outpatient costs or in terms of total GP consultations. The low sample size and
levels of skew in these data may contribute to the nonsignificant difference in the aggregated
totals.
Patient Preference Group. For patients choosing their treatment modality, a sig-
nificant difference between the groups in terms of the overall cost of all depression-related
health services was observed (Table 2) (using the nonparametric test). Patients choosing
counseling incurred higher median costs than patients choosing antidepressants (£225 vs
£184); those mean costs were also higher but not significantly. Direct depression treatment
costs were considerably higher in the counseling group and were not offset by significantly
higher GP consultation costs in the antidepressant group. There is no significant difference
between the treatment groups in terms of psychiatric inpatient or outpatient costs, but again
these data are skewed.
Randomized Versus Patient Preference. For the group of patients receiving an-
tidepressants, no significant overall cost differences between the randomized and patient
preference groups were observed. The only statistically significant difference was in terms
of observed counseling costs. Patients who chose antidepressants initially had lower coun-
seling costs than those randomized to antidepressants. For the group of patients receiving
counseling, no significant overall cost differences between the randomized and patient
preference groups were observed.
Cost-effectiveness Analysis
Point estimates of cost-effectiveness ratios based on the incremental differences in mean
observed cost and effect do not capture uncertainty in the sample data on which they are
based. Confidence intervals for cost data and for effect data are presented, but often not for
cost-effectiveness ratios. Statistical inference from a ratio is difficult, and the policy impli-
cations from point estimates uncertain. The bootstrapping technique generates a distribution
of cost-effectiveness data, which can enable statistical inference and be more informative to
policy decision makers. The 2,000 bootstrapped means for cost and effect pairs are plotted
on the cost-effectiveness plane. Figure 1 shows the range of cost-effectiveness results for an-
tidepressants when compared with counseling (represented by the origin). The proportion of
the distribution in each quadrant informs decision makers of the likelihood of cost and effect
differences between the treatment modalities. For example, a point in the northeast quadrant
shows the case where antidepressants were more costly and more effective than counseling.
Figure 1 shows the distribution around the origin with points in all four quadrants.
To summarize the whole distribution of cost-effectiveness results, a so-called cost-
effectiveness acceptability curve (CEAC) can be constructed (8). This gives an estimate of
the proportion of the simulated distribution of cost and effect pairs that lie below a given
threshold (the maximum value a decision maker is prepared to pay for a unit of effect —K )
or, more simply, the proportion that generate positive net (monetary) benefits. Figure 2 shows
the range of probability that antidepressant therapy will be cost-effective when compared
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Figure 2. Cost-effectiveness acceptability curves: antidepressants compared with counsel-
ing (randomized patients).
with counseling for randomized patients. When decision makers are not prepared to pay
any additional cost to obtain one extra patient with a good outcome (K = 0), there is around
a 0.45 chance that antidepressants will be cost-effective (compared with counseling). This
is the point where the curve intercepts the y-axis and represents the cost difference between
the treatments. It is also shown in Figure 1, since approximately half the data lays either side
of the horizontal axis (45% lower costs and 55% higher costs than counseling). Based on
existing evidence, there is too much uncertainty at this point to claim that antidepressants
are likely to be cost-effective.
However, if decision makers are prepared to pay more for more benefit—additional ef-
fectiveness is valued highly (in monetary terms)—then the probability of cost-effectiveness
increases rapidly. The level of certainty about cost-effectiveness increases asymptotically
for higher values of K. Thus, the probability that antidepressants are more cost-effective is
0.75 when K = £500 and above 0.90 when K > £2,000. The acceptability curve does not
provide information on the magnitude of net benefits, only the proportion of times it is
positive. Mean INMB is negative when k = 0 since the acceptability curve intercepts the
axis below the 0.5 point. Average INMB is substantial as K increases. These data are also
more normally distributed.
Sensitivity Analysis
Two sensitivity analyses were conducted to show the possible impact of unknown out-
come data for randomized patients. Outcome data were missing for 22 randomized patients
(13 counseling, 9 antidepressants); we found their depression-related healthcare resource
use to be significantly lower than patients with 12-month outcome data. The first sensitivity
analysis assumed that all these patients achieved good global outcome. The second anal-
ysis assumed that all these achieved poor global outcome. The bootstrapping simulation
was then used to generate the new distribution for the net benefit statistic. The impact on
the acceptability curve is shown in Figure 2. Assuming good outcomes for missing data
lowers the probability that antidepressants are cost-effective for all values of K. Assuming
poor outcomes for missing data lowers slightly the probability that antidepressants are cost-
effective for values of K< £1,500 but increases the probability for values of K > £1,500.
In both analyses the mean value for net benefit remains positive when K ≥ £500.
88 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 19:1, 2003
Treatment of depression
DISCUSSION
Using conventional analysis, this study found no significant difference between randomized
treatment groups in either outcomes or costs at 12 months. This is in accordance with other
studies (3;7). As with most studies, the CAPC study was powered to detect clinical differ-
ences (Beck scores) between the two treatment groups. Thus, the finding of no statistically
significant differences between the randomized groups in terms of global outcome and cost
to the NHS does not imply that the treatment modalities are equally cost-effective.
Using net-benefits and cost-effectiveness acceptability curves after recalculating mean
costs and effects for both groups by resampling 2,000 times from the observed data provides
decision makers with more information. First, if decision makers are not willing to pay more
for additional benefits (more patients with good global outcome: free from depression),
then given the current evidence we find little difference between the treatment modalities in
terms of cost-effectiveness. Sensitivity analyses show the counseling group is more likely
to be less costly than the antidepressant group. Second, if decision makers do place value
on additional benefit (K > 0), then the antidepressants group becomes more likely to be
cost-effective when compared with the counseling group. This likelihood is in excess of
90% where decision makers are prepared to pay an additional £2,000 or more per additional
patient with a good global outcome. In the most negative sensitivity analysis, the probability
that antidepressants are cost-effective exceeds 0.5 when K = £500 and Rises above 0.75
for higher values of K. As certain antidepressant drugs such as fluoxetine2 come to the end
of their patent protection period, it is possible that their cost may be reduced. This will only
enhance the probability of antidepressants being more cost-effective than counseling.
POLICY IMPLICATIONS
This analysis has shown that for a small proportion of patients with mild to moderate
depression, the counseling intervention (as specified in this trial) is a dominant cost-effective
strategy. For a larger proportion of patients, the antidepressant intervention (as specified in
this trial) is the dominant cost-effective strategy. For the remaining group of patients, cost-
effectiveness depends on the value of K : the amount decision makers value an additional
patient with positive outcome. Since we cannot observe K , acceptability curves are a useful
way to inform decision makers of current evidence in light of their own values. Further
research is needed to understand the determinants of cost-effectiveness for specific groups
of patients. Counseling and/or antidepressants could then be targeted to maximize the overall
efficiency of resources used to manage depression.
NOTES
1 It is conventional to analyze changes brought about by “new” treatment compared with “current”
treatment, so that current treatment is at the origin on the CE plane. We have presented antidepressants
compared with counseling just because of the nature of our data; analysis of counseling compared
with antidepressants (as the origin) would be equally valid.
2 Prozac.
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